These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 24218270)
21. [Role of the complement C3 protein in the control of the specific immune response]. Villiers CL; Villiers MB; Marche PN Ann Biol Clin (Paris); 1999; 57(2):127-35. PubMed ID: 10210739 [TBL] [Abstract][Full Text] [Related]
22. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Imai M; Ohta R; Varela JC; Song H; Tomlinson S Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064 [TBL] [Abstract][Full Text] [Related]
23. Analyses of the in vivo trafficking of stoichiometric doses of an anti-complement receptor 1/2 monoclonal antibody infused intravenously in mice. Whipple EC; Shanahan RS; Ditto AH; Taylor RP; Lindorfer MA J Immunol; 2004 Aug; 173(4):2297-306. PubMed ID: 15294942 [TBL] [Abstract][Full Text] [Related]
24. T cell activation induced by cross-linking CD3 and CD28 leads to silencing of Epstein-Barr virus/C3d receptor (CR2/CD21) gene and protein expression. Masilamani M; von Seydlitz E; Bastmeyer M; Illges H Immunobiology; 2002 Dec; 206(5):528-36. PubMed ID: 12607728 [TBL] [Abstract][Full Text] [Related]
25. IgG antibodies in food allergy influence allergen-antibody complex formation and binding to B cells: a role for complement receptors. Meulenbroek LA; de Jong RJ; den Hartog Jager CF; Monsuur HN; Wouters D; Nauta AJ; Knippels LM; van Neerven RJ; Ruiter B; Leusen JH; Hack CE; Bruijnzeel-Koomen CA; Knulst AC; Garssen J; van Hoffen E J Immunol; 2013 Oct; 191(7):3526-33. PubMed ID: 23997216 [TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus/C3d receptor (CR2, CD21) activated by its extracellular ligands regulates pp105 phosphorylation through two distinct pathways. Bouillie S; Barel M; Drane P; Cassinat B; Balbo M; Holers VM; Frade R Eur J Immunol; 1995 Sep; 25(9):2661-7. PubMed ID: 7589142 [TBL] [Abstract][Full Text] [Related]
27. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. Fang Y; Xu C; Fu YX; Holers VM; Molina H J Immunol; 1998 Jun; 160(11):5273-9. PubMed ID: 9605124 [TBL] [Abstract][Full Text] [Related]
28. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). Mongini PK; Vilensky MA; Highet PF; Inman JK J Immunol; 1997 Oct; 159(8):3782-91. PubMed ID: 9378965 [TBL] [Abstract][Full Text] [Related]
29. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. Kalli KR; Ahearn JM; Fearon DT J Immunol; 1991 Jul; 147(2):590-4. PubMed ID: 1830068 [TBL] [Abstract][Full Text] [Related]
30. Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. Lyubchenko T; dal Porto J; Cambier JC; Holers VM J Immunol; 2005 Mar; 174(6):3264-72. PubMed ID: 15749857 [TBL] [Abstract][Full Text] [Related]
31. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes. Marquart HV; Svehag SE; Leslie RG J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925 [TBL] [Abstract][Full Text] [Related]
32. Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. Nemerow GR; McNaughton ME; Cooper NR J Immunol; 1985 Nov; 135(5):3068-73. PubMed ID: 2995485 [TBL] [Abstract][Full Text] [Related]
33. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies. Tsoukas CD; Lambris JD Eur J Immunol; 1988 Aug; 18(8):1299-302. PubMed ID: 2970972 [TBL] [Abstract][Full Text] [Related]
34. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line. Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586 [TBL] [Abstract][Full Text] [Related]
35. B cell complement receptor 2 transfer reaction. Lindorfer MA; Jinivizian HB; Foley PL; Kennedy AD; Solga MD; Taylor RP J Immunol; 2003 Apr; 170(7):3671-8. PubMed ID: 12646632 [TBL] [Abstract][Full Text] [Related]
36. Cell- and stage-specific chromatin structure across the Complement receptor 2 (CR2/CD21) promoter coincide with CBF1 and C/EBP-beta binding in B cells. Cruickshank MN; Fenwick E; Karimi M; Abraham LJ; Ulgiati D Mol Immunol; 2009 Aug; 46(13):2613-22. PubMed ID: 19487031 [TBL] [Abstract][Full Text] [Related]
37. A complement C3 fragment equivalent to mammalian C3d from the common carp (Cyprinus carpio): generation in serum after activation of the alternative pathway and detection of its receptor on the lymphocyte surface. Nakao M; Miura C; Itoh S; Nakahara M; Okumura K; Mutsuro J; Yano T Fish Shellfish Immunol; 2004 Feb; 16(2):139-49. PubMed ID: 15123318 [TBL] [Abstract][Full Text] [Related]
38. Serum regulates the expression of complement receptor 2 on human B cell lines. Tolnay M; Tsokos GC Immunopharmacol Immunotoxicol; 2000 May; 22(2):205-19. PubMed ID: 10952027 [TBL] [Abstract][Full Text] [Related]
39. Complement receptors CD21 and CD35 in humoral immunity. Roozendaal R; Carroll MC Immunol Rev; 2007 Oct; 219():157-66. PubMed ID: 17850488 [TBL] [Abstract][Full Text] [Related]
40. T lymphocyte expression of complement receptor 2 (CR2/CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Levy E; Ambrus J; Kahl L; Molina H; Tung K; Holers VM Clin Exp Immunol; 1992 Nov; 90(2):235-44. PubMed ID: 1424280 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]